Response assessment criteria and their applications in lymphoma: Part 1

Mateen C. Moghbel, Lale Kostakoglu, Katherine Zukotynski, Delphine L. Chen, Helen Nadel, Ryan Niederkohr, Erik Mittra

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The effectiveness of cancer therapy, both in individual patients and across populations, requires a systematic and reproducible method for evaluating response to treatment. Early efforts to meet this need resulted in the creation of numerous guidelines for quantifying posttherapy changes in disease extent, both anatomically and metabolically. Over the past few years, criteria for disease response classification have been developed for specific cancer histologies. To date, the spectrum of disease broadly referred to as lymphoma is perhaps the most common for which disease response classification is used. This review article provides an overview of the existing response assessment criteria for lymphoma and highlights their respective methodologies and validities. Concerns over the technical complexity and arbitrary thresholds of many of these criteria, which have impeded the long-standing endeavor of standardizing response assessment, are also discussed.

Original languageEnglish (US)
Pages (from-to)928-935
Number of pages8
JournalJournal of Nuclear Medicine
Volume57
Issue number6
DOIs
StatePublished - Jun 1 2016
Externally publishedYes

Fingerprint

Lymphoma
Neoplasms
Histology
Guidelines
Therapeutics
Population

Keywords

  • CT
  • Lymphoma
  • PERCIST
  • PET
  • RECIST

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Moghbel, M. C., Kostakoglu, L., Zukotynski, K., Chen, D. L., Nadel, H., Niederkohr, R., & Mittra, E. (2016). Response assessment criteria and their applications in lymphoma: Part 1. Journal of Nuclear Medicine, 57(6), 928-935. https://doi.org/10.2967/jnumed.115.166280

Response assessment criteria and their applications in lymphoma : Part 1. / Moghbel, Mateen C.; Kostakoglu, Lale; Zukotynski, Katherine; Chen, Delphine L.; Nadel, Helen; Niederkohr, Ryan; Mittra, Erik.

In: Journal of Nuclear Medicine, Vol. 57, No. 6, 01.06.2016, p. 928-935.

Research output: Contribution to journalArticle

Moghbel, MC, Kostakoglu, L, Zukotynski, K, Chen, DL, Nadel, H, Niederkohr, R & Mittra, E 2016, 'Response assessment criteria and their applications in lymphoma: Part 1', Journal of Nuclear Medicine, vol. 57, no. 6, pp. 928-935. https://doi.org/10.2967/jnumed.115.166280
Moghbel MC, Kostakoglu L, Zukotynski K, Chen DL, Nadel H, Niederkohr R et al. Response assessment criteria and their applications in lymphoma: Part 1. Journal of Nuclear Medicine. 2016 Jun 1;57(6):928-935. https://doi.org/10.2967/jnumed.115.166280
Moghbel, Mateen C. ; Kostakoglu, Lale ; Zukotynski, Katherine ; Chen, Delphine L. ; Nadel, Helen ; Niederkohr, Ryan ; Mittra, Erik. / Response assessment criteria and their applications in lymphoma : Part 1. In: Journal of Nuclear Medicine. 2016 ; Vol. 57, No. 6. pp. 928-935.
@article{6ca751ad28e24f91adf1cc6bc0aa4d8e,
title = "Response assessment criteria and their applications in lymphoma: Part 1",
abstract = "The effectiveness of cancer therapy, both in individual patients and across populations, requires a systematic and reproducible method for evaluating response to treatment. Early efforts to meet this need resulted in the creation of numerous guidelines for quantifying posttherapy changes in disease extent, both anatomically and metabolically. Over the past few years, criteria for disease response classification have been developed for specific cancer histologies. To date, the spectrum of disease broadly referred to as lymphoma is perhaps the most common for which disease response classification is used. This review article provides an overview of the existing response assessment criteria for lymphoma and highlights their respective methodologies and validities. Concerns over the technical complexity and arbitrary thresholds of many of these criteria, which have impeded the long-standing endeavor of standardizing response assessment, are also discussed.",
keywords = "CT, Lymphoma, PERCIST, PET, RECIST",
author = "Moghbel, {Mateen C.} and Lale Kostakoglu and Katherine Zukotynski and Chen, {Delphine L.} and Helen Nadel and Ryan Niederkohr and Erik Mittra",
year = "2016",
month = "6",
day = "1",
doi = "10.2967/jnumed.115.166280",
language = "English (US)",
volume = "57",
pages = "928--935",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "6",

}

TY - JOUR

T1 - Response assessment criteria and their applications in lymphoma

T2 - Part 1

AU - Moghbel, Mateen C.

AU - Kostakoglu, Lale

AU - Zukotynski, Katherine

AU - Chen, Delphine L.

AU - Nadel, Helen

AU - Niederkohr, Ryan

AU - Mittra, Erik

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The effectiveness of cancer therapy, both in individual patients and across populations, requires a systematic and reproducible method for evaluating response to treatment. Early efforts to meet this need resulted in the creation of numerous guidelines for quantifying posttherapy changes in disease extent, both anatomically and metabolically. Over the past few years, criteria for disease response classification have been developed for specific cancer histologies. To date, the spectrum of disease broadly referred to as lymphoma is perhaps the most common for which disease response classification is used. This review article provides an overview of the existing response assessment criteria for lymphoma and highlights their respective methodologies and validities. Concerns over the technical complexity and arbitrary thresholds of many of these criteria, which have impeded the long-standing endeavor of standardizing response assessment, are also discussed.

AB - The effectiveness of cancer therapy, both in individual patients and across populations, requires a systematic and reproducible method for evaluating response to treatment. Early efforts to meet this need resulted in the creation of numerous guidelines for quantifying posttherapy changes in disease extent, both anatomically and metabolically. Over the past few years, criteria for disease response classification have been developed for specific cancer histologies. To date, the spectrum of disease broadly referred to as lymphoma is perhaps the most common for which disease response classification is used. This review article provides an overview of the existing response assessment criteria for lymphoma and highlights their respective methodologies and validities. Concerns over the technical complexity and arbitrary thresholds of many of these criteria, which have impeded the long-standing endeavor of standardizing response assessment, are also discussed.

KW - CT

KW - Lymphoma

KW - PERCIST

KW - PET

KW - RECIST

UR - http://www.scopus.com/inward/record.url?scp=84973636384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973636384&partnerID=8YFLogxK

U2 - 10.2967/jnumed.115.166280

DO - 10.2967/jnumed.115.166280

M3 - Article

C2 - 27127227

AN - SCOPUS:84973636384

VL - 57

SP - 928

EP - 935

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 6

ER -